Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SRRA Sierra Oncology, Inc. daily Stock Chart
SRRA [NASD]
Sierra Oncology, Inc.
Healthcare | Biotechnology | Canada
statements
Index- P/E- EPS (ttm)-19.47 Insider Own0.10% Shs Outstand10.40M Perf Week4.17%
Market Cap131.45M Forward P/E- EPS next Y-5.99 Insider Trans- Shs Float9.97M Perf Month20.85%
Income-108.70M PEG- EPS next Q-1.64 Inst Own79.50% Short Float0.10% Perf Quarter-2.45%
Sales- P/S- EPS this Y-0.50% Inst Trans- Short Ratio0.42 Perf Half Y7.96%
Book/sh11.22 P/B1.14 EPS next Y21.60% ROA-89.40% Target Price- Perf Year8.42%
Cash/sh11.95 P/C1.07 EPS next 5Y- ROE-111.10% 52W Range8.55 - 22.00 Perf YTD-6.91%
Dividend- P/FCF- EPS past 5Y-7.90% ROI- 52W High-42.05% Beta1.53
Dividend %- Quick Ratio13.90 Sales past 5Y- Gross Margin- 52W Low49.21% ATR0.50
Employees71 Current Ratio13.90 Sales Q/Q- Oper. Margin- RSI (14)65.25 Volatility3.45% 4.29%
OptionableNo Debt/Eq0.00 EPS Q/Q80.10% Profit Margin- Rel Volume0.32 Prev Close12.42
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume22.87K Price12.75
Recom1.50 SMA2011.59% SMA509.55% SMA2003.42% Volume7,385 Change2.66%
Jul-30-20Initiated H.C. Wainwright Buy $20
Dec-06-19Initiated Oppenheimer Outperform $1.20
Oct-23-17Upgrade Jefferies Hold → Buy
Mar-10-17Upgrade SunTrust Hold → Buy
Feb-22-17Resumed Wedbush Outperform $3 → $4
Oct-02-20 07:00AM  
Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
07:00AM  
Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CNW Group
Sep-14-20 07:00AM  
Sierra to Present at September Investor Conferences
PR Newswire +10.96%
07:00AM  
Sierra to Present at September Investor Conferences
CNW Group
Sep-04-20 03:47PM  
What You Need To Know About Sierra Oncology, Inc.'s (NASDAQ:SRRA) Investor Composition
Simply Wall St.
Aug-06-20 07:05AM  
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib
PR Newswire
07:00AM  
Sierra Oncology Reports Second Quarter 2020 Results
PR Newswire
Jul-28-20 07:00AM  
Sierra Oncology Appoints Christina Thomson as General Counsel
GlobeNewswire
Jun-26-20 11:44AM  
Sierra Oncology, Inc. (SRRA): Hedge Funds In Wait-and-See Mode
Insider Monkey
Jun-18-20 12:00PM  
Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
Jun-16-20 04:05PM  
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
GlobeNewswire
Jun-12-20 02:30AM  
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
PR Newswire +7.51%
02:30AM  
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib
CNW Group
May-27-20 07:00AM  
Sierra Oncology Announces Presentations at Upcoming Investor Conferences
PR Newswire
07:00AM  
Sierra Oncology Announces Presentations at Upcoming Investor Conferences
CNW Group
May-26-20 07:00AM  
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
PR Newswire
07:00AM  
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
CNW Group
May-14-20 09:00AM  
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress
PR Newswire
May-07-20 08:00AM  
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
PR Newswire
08:00AM  
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis
CNW Group
07:00AM  
Sierra Oncology Reports First Quarter 2020 Results
CNW Group
May-04-20 12:45PM  
Here's Why We're Not Too Worried About Sierra Oncology's (NASDAQ:SRRA) Cash Burn Situation
Simply Wall St. +11.00%
Apr-21-20 05:31PM  
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
GuruFocus.com
Mar-03-20 07:00AM  
Sierra Oncology Reports 2019 Year End Results
PR Newswire
Feb-26-20 08:47AM  
Why Earnings Season Could Be Great for Sierra Oncology (SRRA)
Zacks
07:00AM  
Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call
CNW Group
Feb-25-20 07:00AM  
Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference
CNW Group -8.40%
Feb-11-20 07:23AM  
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
Benzinga +19.88%
Feb-06-20 07:00AM  
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
CNW Group
Jan-28-20 07:09AM  
Sierra Oncology Sees Hammer Chart Pattern: Time to Buy?
Zacks +5.32%
Jan-22-20 07:00AM  
Sierra Oncology Announces Reverse Stock Split
PR Newswire -11.14%
Jan-06-20 02:17PM  
5 More Deep-Value Stocks for 2020
GuruFocus.com
Dec-19-19 06:08PM  
Here is What Hedge Funds Think About Sierra Oncology, Inc. (SRRA)
Insider Monkey
Dec-07-19 09:00AM  
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
PR Newswire
09:00AM  
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
CNW Group
Dec-02-19 07:00AM  
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
CNW Group +44.22%
Nov-26-19 07:00AM  
Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors
PR Newswire +10.27%
Nov-20-19 07:00AM  
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
PR Newswire
Nov-14-19 04:05PM  
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
PR Newswire
04:05PM  
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
CNW Group
Nov-07-19 09:02AM  
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
PR Newswire -27.94%
09:01AM  
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants
PR Newswire
09:01AM  
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants
CNW Group
Nov-06-19 04:01PM  
Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants
PR Newswire +6.92%
04:01PM  
Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants
CNW Group
09:00AM  
Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019
CNW Group
Nov-04-19 04:01PM  
Sierra Oncology Reports Third Quarter 2019 Results
PR Newswire
04:01PM  
Sierra Oncology Reports Third Quarter 2019 Results
CNW Group
Sep-13-19 12:00PM  
Do Institutions Own Shares In Sierra Oncology, Inc. (NASDAQ:SRRA)?
Simply Wall St.
Aug-08-19 07:00AM  
Sierra Oncology Reports Second Quarter 2019 Results
PR Newswire
Aug-07-19 07:00AM  
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York
PR Newswire
Jul-15-19 03:03PM  
Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?
Simply Wall St. -8.14%
Jun-29-19 11:33PM  
Hedge Funds Have Never Been More Bullish On Sierra Oncology, Inc. (SRRA)
Insider Monkey
Jun-27-19 07:00AM  
Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets
PR Newswire
07:00AM  
Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets
CNW Group
Jun-05-19 06:00AM  
Sierra Announces Momelotinib Granted FDA Fast Track Designation
PR Newswire -7.84%
06:00AM  
Sierra Announces Momelotinib Granted FDA Fast Track Designation
CNW Group
Jun-04-19 05:04PM  
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial
PR Newswire
05:04PM  
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial
CNW Group
Jun-03-19 07:00AM  
Sierra Holds Analyst & Investor Event for SRA737
PR Newswire -23.89%
07:00AM  
Sierra Holds Analyst & Investor Event for SRA737
CNW Group
Jun-01-19 09:00AM  
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration
PR Newswire
May-28-19 07:00AM  
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
PR Newswire -7.97%
07:00AM  
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
CNW Group
May-15-19 05:00PM  
Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO
PR Newswire +6.99%
May-08-19 07:53AM  
Sierra Oncology, Inc: 1Q Earnings Snapshot
Associated Press
07:00AM  
Sierra Oncology Reports First Quarter 2019 Results
PR Newswire
07:00AM  
Sierra Oncology Reports First Quarter 2019 Results
CNW Group
May-06-19 07:00AM  
Sierra Oncology to Attend Two Investor Conferences in May
CNW Group
Apr-26-19 11:55AM  
Imagine Owning Sierra Oncology (NASDAQ:SRRA) And Trying To Stomach The 72% Share Price Drop
Simply Wall St.
Apr-03-19 08:00AM  
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
CNW Group
Apr-01-19 04:05PM  
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019
PR Newswire
04:05PM  
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019
CNW Group
Mar-05-19 07:00AM  
Sierra Oncology to Present at the Cowen 39th Annual Health Care Conference in Boston
CNW Group
Feb-28-19 07:00AM  
Sierra Oncology Reports 2018 Year End Results
CNW Group +6.59%
Feb-27-19 04:30PM  
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
CNW Group +5.20%
Jan-23-19 07:00AM  
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
CNW Group
Jan-22-19 10:24AM  
Do Institutions Own Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?
Simply Wall St.
Dec-03-18 07:00AM  
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
PR Newswire
07:00AM  
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
CNW Group
Nov-29-18 05:00PM  
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
CNW Group
Nov-27-18 05:00PM  
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit
CNW Group
Nov-22-18 12:11PM  
How Does Sierra Oncology Inc (NASDAQ:SRRA) Affect Your Portfolio Volatility?
Simply Wall St.
Nov-15-18 05:00AM  
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium
PR Newswire
Nov-13-18 07:00AM  
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium
CNW Group
Nov-08-18 07:00AM  
Sierra Oncology Reports Third Quarter Results
CNW Group
Nov-07-18 07:00AM  
Sierra Oncology to Present at the Jefferies 2018 London Healthcare Conference
CNW Group
Nov-01-18 09:20AM  
Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients
PR Newswire +5.26%
Oct-04-18 07:00AM  
Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"
PR Newswire
Aug-30-18 07:24AM  
Sierra Oncology (SRRA): Moving Average Crossover Alert
Zacks
Aug-22-18 05:32PM  
Gilead paid $510M for drug and just sold it for $3 million
American City Business Journals
07:05AM  
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
PR Newswire
07:00AM  
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
CNW Group
Aug-09-18 07:00AM  
Sierra Oncology Reports Second Quarter Results
PR Newswire -10.64%
Aug-07-18 07:00AM  
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York
CNW Group
Jul-23-18 07:05AM  
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
ACCESSWIRE
Jul-19-18 05:57AM  
ProNAi Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Zacks
Jun-26-18 07:15AM  
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
ACCESSWIRE
Jun-01-18 09:42AM  
Can The Uptrend Continue for Sierra Oncology (SRRA)?
Zacks
May-25-18 07:10AM  
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks
ACCESSWIRE
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klencke BarbaraChief Development OfficerAug 18Buy12.253,32540,7385,000Aug 18 08:16 PM
Klencke BarbaraChief Development OfficerAug 18Buy12.225,95072,71010,000Aug 18 08:16 PM
open in yahoo | open in reuters | open in google
affiliate | advertise | contact | privacy | help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.